7 results
Primary Objective: Development of a tracer kinetic model for tracers [11C]DPA-713 and [18F]PEG-Folate.Secondary Objectives: 1. Development of a static imaging protocol and a validated simplified measure for quantification of uptake of tracers [11C]…
The primary objective of this study is to evaluate the dose response, dose interval, efficacy, and safety of GSK961081 by studying three QD doses and three BID doses in subjects with COPD. The study will also evaluate the population PK, systemic PK-…
Primary: Efficacy of FF/GW642444 100/25 mcg once daily in comparison with that of FP/salmeterol 250/50 mcg twice daily during 24 weeks.Secundary: Safety and tolerability.
To demonstrate superiority of tiotropium vs. salmeterol in reducing exacerbations which are an important patient outcome because they are a major cause of morbidity from COPD. In addition, they are associated with a more rapid decline in lung…
This study will evaluate the long-term safety and tolerability of IVT faricimab in patients with nAMD who have completed either of the Phase III (GR40306 or GR40844) studies. Additional assessments relating to efficacy, pharmacokinetics,…
Primary:To compare the effect of UMEC/VI (62.5/25 mcg once daily) with UMEC (62.5 mcg once daily) on lung functionSecondary:To compare UMEC/VI, UMEC with salmeterol (50 mcg twice daily) on patient reported outcomes and on other COPD efficacy…
The purpose of this study is to investigate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at up to 16-week intervals to treatment-naive patients with nAMD.